ERBB2 and breast carcinoma: They compared the fluorophore conjugated anti-HER2 antibody, trastuzumab, to 11A4-IR800 in subcutaneous breast cancer mouse models and again showed that nanobodies have an advantage in timing of tumor labeling and contrast.